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Abstract: Magnetic resonance imaging (MRI) can detect atherosclerotic lesions containing 
accumulations of ultrasmall superparamagnetic iron oxides (USPIO). Positing that improved 
USPIO with a higher affinity for atherosclerotic plaques would yield better plaque images, we 
performed MRI and histologic studies to compare the uptake of dextran- and mannan–dextran-
coated USPIO (D-USPIO and DM-USPIO, respectively) by the atherosclerotic walls of rabbits. 
We intravenously injected atherosclerotic rabbits with DM-USPIO (n = 5) or D-USPIO (n = 5). 
Two rabbits were the controls. The doses delivered were 0.08 (dose 1) (n = 1), 0.4 (dose 2) 
(n = 1), or 0.8 (dose 3) (n = 3) mmol iron/Kg. The dose 3 rabbits underwent in vivo contrast-
enhanced magnetic resonance angiography (MRA) before and 5 days after USPIO administration. 
Afterwards, all animals were euthanized, the aortae were removed and subjected to in vitro MRI 
study. The signal-to-noise ratio (SNR) of the aortic wall in the same region of interest (ROI) was 
calculated in both in vivo and in vitro studies. Histological assessment through measurement of 
iron-positive regions in Prussian blue-stained specimens showed that iron-positive regions were 
significantly larger in rabbits injected with DM- rather than D-USPIO (P , 0.05) for all doses. 
In vivo MRA showed that the SNR-reducing effect of DM- was greater than that of D-USPIO 
(P , 0.05). With in vitro MRI scans, SNR was significantly lower in rabbits treated with dose 
2 of DM-USPIO compared with D-USPIO treatment (P , 0.05), and it tended to be lower at 
dose 3 (P , 0.1). In conclusion, we suggest that DM-USPIO is superior to D-USPIO for the 
study of atherosclerotic lesions in rabbits.
Keywords: atherosclerosis, magnetic resonance imaging, contrast media, plaque, mannan–
dextran-coated USPIO
Introduction
Atherosclerosis is a chronic inflammatory response to vessel wall injury, leading 
potentially, to acute coronary syndrome and cerebral vascular disorders, induced by 
plaque rupture. The noninvasive imaging of atherosclerotic plaque progression and of 
therapeutic response is very important. In atherosclerosis, macrophage accumulation 
initiates lesion development and triggers clinical events by producing several molecules 
that promote inflammation, plaque disruption, and subsequent thrombus formation.1–4 
However, conventional anatomic measurements of advanced lesions (eg, plaque size or 
luminal narrowing) do not necessarily correlate with macrophage content. It is desirable 
that imaging of macrophages permits the identification of highly activated plaques, to 
help in the prediction of acute thrombotic events, and to facilitate assessment of the 
therapeutic effects of antiatherosclerotic drugs, such as statins. In hyperlipidemic rabbits 
and humans, atherosclerotic plaques have been investigated using magnetic resonance 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2271
ORIgINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S29417International Journal of Nanomedicine 2012:7
imaging (MRI), using ultrasmall superparamagnetic iron 
oxides (USPIO): iron oxide nanoparticles stabilized with 
low-molecular-weight dextran, having a mean diameter 
of 30 nm.5–8 As these relatively small particles are not 
immediately recognized by the hepatic and splenic 
mononuclear phagocytic systems (MPS),9,10 the prolongation 
of their intravascular half-life permits their uptake, via 
macrophages, by the whole body, including the lymph 
nodes, lungs, and the walls of atherosclerotic vessels.5–8,11,12 
With respect to the excretion pathway, USPIO particles 
are internalized by receptor-mediated endocytosis, and 
metabolized via the lysosomal pathway.13 On internalization 
by macrophages, the dextran coating is progressively 
degraded; 89% is eliminated in urine, and the rest is excreted 
in feces. The iron contained in USPIO is incorporated into the 
body’s iron store and used in hemoglobin manufacture. Like 
endogenous iron, it is eliminated very slowly, predominantly 
via the feces.14 Based on USPIO-associated T2- and T2*-
shortening effects, atherosclerotic lesions with accumulated 
USPIO can be detected on MRI scans. Higher doses tended 
to be administered in earlier animal studies. We posited that 
improved USPIO with higher affinity for atherosclerotic 
plaques would make it possible to obtain better images of 
plaques at lower doses.
The effectiveness of iron oxide nanoparticles, which 
conjugate with various biomolecules, has been studied 
previously in investigations of novel therapeutic actions and 
drug delivery, for example, in blood purification therapy 
and drug treatments for cancer and hyperthermia.15–25 
According to Bouhlel et al,26 the mannose receptors of 
M2 macrophages are more abundantly expressed in patho-
logical tissues of atherosclerotic lesions than in the adjacent 
zone. Therefore, we focused on mannan–dextran-coated 
USPIO (DM-USPIO), prepared in-house by adding alkali-
treated mannan to dextran-coated USPIO (D-USPIO). Our 
working hypothesis posited that the addition of mannan to 
D-USPIO would facilitate its uptake by macrophage-rich 
atherosclerotic plaques. Here, we performed MRI and his-
topathological studies to compare the uptake of DM-USPIO 
with that of D-USPIO in atherosclerotic plaques of rabbits.
Material and methods
All experimental protocols were approved by our   Animal 
Experimentation Committee. All experiments were 
  conducted in accordance with the Animal Care Guidelines 
of Shiga University of Medical Science.
Iron oxide nanoparticles
We studied two kinds of iron oxide: DM-USPIO and 
D-USPIO (supplied by Meito Sangyo, Kiyosu, Aichi, Japan). 
Superparamagnetic iron oxide (SPIO) is a widely-used, safe, 
liver-specific contrast medium (Resovist®; Bayer Health 
Care Japan, Osaka, Japan);27 carboxydextran covers the 
iron core of the iron oxide particles. The particle size of the 
D-USPIO used in this study is different from that of SPIO 
but its composition is similar. We prepared DM-USPIO by 
adding alkali-treated mannan to D-USPIO (Figure 1). The 
particle size, iron concentration, and magnetic susceptibility 
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Figure 1 Illustration of D-USPIO and DM-USPIO. 
Note: DM-USPIO was prepared in-house by adding alkali-treated mannan to D-USPIO. 
Abbreviations: D-USPIO, dextran-coated ultrasmall superparamagnetic iron oxide; DM-USPIO, mannan–dextran-coated ultrasmall superparamagnetic iron oxide.
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were the same for D- and DM-USPIO (28 nm, 15 mg/mL, 
0.028 erg ⋅ gauss-2 ⋅ g-1, respectively).
Preparation of D- and DM-USPIO
To obtain D-USPIO, 84 g of carboxydextran (molecular 
weight: 2500, approximately) was dissolved in 150 mL of 
water. To this was added an aqueous solution obtained by 
dissolving 17 g of ferrous chloride tetrahydrate in 130 mL of 
a 1 M aqueous ferric chloride solution under a nitrogen gas 
stream. Then, 220 mL of a 3 N aqueous solution of sodium 
hydroxide was added, with heating and stirring. The mixture 
was adjusted to pH 7.0 by adding 6 N hydrochloric acid, and 
then refluxed for 1.5 hours. The reaction mixture was sub-
jected to centrifugation at 2500 × g for 1 hour, and the super-
natant liquid then subjected to ultrafiltration   (Centramate™; 
Pall Corporation, Long Island, NY) (molecular weight cut-off 
[MWCO]: 100,000) to obtain 1 L of D-USPIO.
To create DM-USPIO we added 500 mL of D-USPIO 
solution (iron concentration: 30 mg/mL) to 15 g of mannan 
prepared by extraction from beer yeast and refluxed for 
5 hours. The reaction mixture was then subjected to 
ultrafiltration (MWCO: 100,000) to obtain 500 mL of 
DM-USPIO.
In vivo MRI
We used six Watanabe heritable hyperlipidemic (WHHL) 
rabbits obtained from the Institute for Experimental Animals 
at Kobe University, Hyogo, Japan. Each was 9–12 months 
old and weighed approximately 3 kg. At this age, WHHL 
rabbits harbor active plaque formations in the aortic wall.28 
They were divided into two equal groups and injected 
intravenously with 0.8 mmol iron (Fe)/kg (dose 3) of D- or 
DM-USPIO. Gadolinium-enhanced magnetic resonance 
angiography (MRA) scans were obtained before and 5 days 
after the injection. For each MRI session, the rabbits were 
fully anesthetized with ketamine (Ketalar; Daiichi Sankyo, 
Tokyo, Japan), at 25 mg/kg body weight, and medetomidine 
(Domitor; Nippon Zenyaku Kogyo, Koriyama, Fukushima, 
Japan), at 0.1 mg/kg body weight, then injected intravenously 
with 2 mL gadopentetate dimeglumine (Magnevist®; Bayer 
Health Care Japan), diluted in 10 mL saline.
All scans were obtained using a 1.5T MRI system, using 
a transmit-receive coil (Magnetom Sonata; Siemens   Medical 
Solutions, Erlangen, Germany) (maximum amplitude: 
40 mT m-1; slew rate: 200 mT m-1 msec-1). For imaging, we 
used a fast low-angle shot (FLASH) protocol. The parameters 
used were: TR, 4.3 ms; TE, 1.7 ms; flip angle, 25°; field of 
view (FOV), 320 × 200 mm; matrix size, 512 × 320; and slice 
thickness, 1 mm. The source images were made available for 
analysis on a workstation that allowed interactive multiplanar 
reformatting of the data sets.
For quantitative analysis, we calculated the signal-to-noise 
ratio (SNR) in the same three regions of interest (ROI) 
(3 × 20 pixels) in the aortic wall of the lower intrathoracic 
aorta in three different coronal reformatted images. We 
compared the SNR yielded by both types of USPIO.
In vitro MRI
Of the twelve WHHL rabbits, ten were divided into two 
equal groups, and injected with D- or DM-USPIO at three 
different doses: 0.08 (dose 1) (n = 1), 0.4 (dose 2) (n = 1), 
or 0.8 (dose 3) (n = 3) mmol Fe/kg. Two were untreated 
and served as controls. The animals were euthanized 5 days 
post-injection, and MRI scans of resected aortic specimens 
were obtained.
The specimens were placed in centrifuge tubes filled with 
gadopentetate dimeglumine (1:50 dilution) and 10% gelatin 
by weight. MRI was performed using a 1.5T MRI scanner, 
using a 1-channel loop coil (Signa HDxt; GE   Healthcare, 
Little Chalfont, UK). Imaging was achieved using the 
three-dimensional (3D) first-spoiled GRASS   protocol. 
The parameters used were: TR, 11.8 ms; TE, 4.1 ms; flip 
angle, 30°; FOV , 5 × 5 cm; matrix size, 512 × 512; slice 
thickness, 1 mm. Source images were made available for 
analysis on a workstation that enabled interactive multiplanar 
reformatting of the data sets.
For quantitative analysis we calculated the SNR at three 
ROIs (3 × 20 pixels) in the wall of the lower intrathoracic 
aorta in three different coronal reformatted images. We 
compared the results obtained after three different doses of 
D- and DM-USPIO.
Histological examination
Aortic specimens were fixed in 10% paraformaldehyde. 
From five different lesions on the lower thoracic aorta, we 
cut paraffin-embedded 4 µm thick sections on the axial 
plane. These were stained with Prussian blue to identify the 
accumulation of iron oxide. We also stained macrophages 
immunohistochemically with RAM11, and compared 
Prussian blue- and RAM11-stained areas. For quantitative 
assessment, we measured the Prussian blue-stained area in 
one FOV (magnification, 200×) in three different lesions 
for each histological section of the lower intrathoracic 
aorta (using Image-Pro Plus; Media Cybernetics, Silver 
Spring, MD), and calculated the average values. In addition, 
the amount of iron per unit weight (300 µg) of the lower 
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intrathoracic aortic specimens of dose 3 rabbits was measured 
by nuclear magnetic resonance (Minispec MQ20; Bruker 
Optics, Billerica, MA) (20 MHz, 0.47 T).
To acquire additional data on the biodistribution of D-   
and DM-USPIO, we examined tissues from the liver, spleen, 
lung, kidney, and heart of rabbits which had undergone in vivo 
MRI study and had received dose 3 of either D- or DM-
USPIO (n = 3, respectively); two rabbits treated with   neither 
D- nor DM-USPIO were the controls. These specimens 
were fixed in 10% paraformaldehyde.   Paraffin-embedded 
4-µm-thick sections were cut in the axial plane and stained 
with   Prussian blue. We assessed one section for each organ. 
Prussian blue-stained areas were measured and evaluated as 
described above.
Uptake by cultured cells
To compare the phagocytosis of D- and DM-USPIO, we used 
the murine macrophage cell line, J774.1 (RIKEN Cell Bank; 
Wako, Saitama, Japan), which is widely used in research on 
macrophages.29–31 Cells (8 × 105) were seeded in 12 multiwell 
cluster plates (Corning Inc., Corning, NY) and grown at 37°C 
for 24 hours in 1 mL growth medium (RPMI; Nacalai Tesque, 
Kyoto, Japan), supplemented with 10% bovine fetal calf serum 
by volume (Invitrogen, Carlsbad, CA) and 1% by weight mixed 
penicillin and streptomycin solution (Nacalai Tesque). The 
medium was then replaced with fresh medium. D-USPIO or 
DM-USPIO (10 µg iron oxide and 100 µL, respectively) were 
added, and the plates incubated for 1 hour for cell labeling. 
The medium was again replaced and the wells incubated for 
24 hours. To identify intracellular iron oxide accumulations, 
the cells were stained with Prussian blue. The amount of iron 
contained in cell lysates was measured by atomic absorp-
tion photometry (AA-6800; Shimadzu, Kyoto, Japan). Cell 
labeling was performed as described in a previous study.32
Statistical analysis
We used SPSS for Windows software (SPSS Japan, Tokyo, 
Japan) for statistical analysis. Differences in the uptake of 
D- and DM-USPIO in the arterial wall, in the uptake of iron 
by cultured macrophages, and in the SNR values from MRA 
scans obtained in vivo and in vitro were determined using 
the one-tailed Student’s t-test. A P-value of P , 0.05 was 
considered statistically significant.
Results
In vivo MRI
In rabbits treated with dose 3 of D- or DM-USPIO (n = 3, 
respectively), MRA images obtained in vivo showed 
irregularities, seen as spotty signal voids in the aortic wall. 
These were interpreted as indicating iron deposits. Before 
treatment with either agent, the aortic wall appeared smooth, 
without any evidence of atherosclerotic plaque formation. 
The SNR of the aortic wall was significantly lower after 
treatment with D- and DM-USPIO than before treatment. 
The difference between the SNR obtained before and 
after the injection of nanoparticles was significantly greater 
in rabbits treated with DM- rather than D-USPIO (P , 0.05) 
(Figure 2).
In vitro MRI
The aortic walls of the control animals were smooth, and 
the signal emitted was relatively high. In contrast, signal 
strength decreased in a dose-dependent fashion in rabbits 
injected with D- or DM-USPIO. At dose 3, the SNR tended 
to be lower in rabbits injected with DM- than with D-USPIO 
(P , 0.1). At dose 2 DM-USPIO, the SNRs obtained from 
three ROIs on three different aortic images were significantly 
lower than those of the rabbit treated with an equivalent 
dose of D-USPIO (P , 0.05). At dose 1, there was no sta-
tistically significant difference (P . 0.1) (Figure 3). These 
findings indicate that the uptake of either type of USPIO 
produced a decrease in SNR.
Histological examination
Prussian blue-stained histopathological sections showed 
marked  iron  uptake  by  macrophages  embedded  in 
atherosclerotic plaques in the aortic walls of rabbits injected 
with either type of USPIO. This was not the case in the 
control animals. Iron uptake was dose-dependent (Figure 4). 
Immunohistochemical staining (RAM11) showed that the 
localization of iron deposits and of macrophages coincided 
(Figure 5). Quantitative analysis of iron-positive areas in 
the aortic wall revealed that they were significantly larger 
in rabbits treated with dose 3 DM- than in those treated 
with dose 3 D-USPIO (P , 0.05). In addition, in different 
aortic sections, these areas were significantly larger in the 
rabbit treated with dose 1 or dose 2 DM-USPIO than in that   
treated with an equivalent dose of D-USPIO (P , 0.05) 
(Figure 6). At dose 3 of D- and DM-USPIO, the amount of 
iron accumulated per unit weight of aortic specimen was 
not different (Figure 7).
There was no statistically significant difference in 
the biodistribution of D- and DM-USPIO in tissues from 
the spleen and kidney. The values determined by Prussian 
blue staining in tissues of the spleen were 40,088 ± 10,480 
vs 43,607 ± 9456 for D- and DM-USPIO, respectively, and 
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were 1711 ± 1508 vs 758 ± 583, respectively, in kidney 
tissues. In the liver and lung, these values tended to be higher 
in DM- than D-USPIO-treated rabbits (18,118 ± 5027 vs 
14,421 ± 5920 in the liver, and 1261 ± 1363 vs 169 ± 245 
in the lung). There was no significant iron accumulation in 
cardiac tissues. In the controls, only the spleen (the iron-
storing organ) showed significant iron deposits. In both 
D- and DM-USPIO-treated rabbits these levels were 
increased.
Uptake by cultured cells
Microscopically, almost all cultured (J774.1) cells phago-
cytosed both D- and DM-USPIO. However, the amount of 
intracellular iron measured by atomic absorption photometry 
was significantly higher in cells treated with DM- rather than 
D-USPIO (Figure 8) (P < 0.05).
Discussion
Our experimental study showed that, in WHHL rabbits, 
both D- and DM-USPIO particles were phagocytosed by 
macrophages embedded in atherosclerotic plaques. This 
leads to a susceptibility-induced signal reduction in the 
atherosclerotic vessel wall on T1-weighted 3D gradient 
echo (GRE) images. In the T1-weighted fast 3D GRE 
sequence, T1 shortening is a characteristic of lower USPIO 
concentration. This renders the signal bright, and produces 
a predominant T2/T2* shortening at higher concentrations, 
resulting in a completely dark signal.33 Consequently, at 
the initial stage of USPIO administration, the signal of 
the aortic lumen is completely dark due to a high blood 
concentration of USPIO. According to Ruehm et al,5 the 
uptake by the MPS of USPIO particles over a 4- to 5-day 
period creates an ideal situation for imaging the vascular wall. 
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Figure 2 In vivo MRA of the thoracic aorta of WHHL rabbits, (A) before, and (B) after the administration of D-USPIO, and (C) before, and (D) after the administration 
of DM-USPIO. 
Notes: Irregularities, seen as spotty signal voids in the aortic wall, are present on the images obtained after administration of D- or DM-USPIO. The graph compares 
pre- and post-administration SNR measurements in the ROI in the aortic wall of WHHL rabbits subjected to in vivo MRI (n = 6), after injection with D- or DM-USPIO 
(n = 3, respectively). The SNR values were significantly lower on all post-contrast images. In rabbits injected with DM-USPIO, the difference between the pre- and post- 
administration SNR values was significantly greater than in those treated with D-USPIO *P , 0.05.
Abbreviations:  D-USPIO,  dextran-coated  ultrasmall  superparamagnetic  iron  oxide;  DM-USPIO,  mannan–dextran-coated  ultrasmall  superparamagnetic  iron  oxide;   
MRA, magnetic resonance angiography; SNR, signal-to-noise ratio; ROI, region of interest; MRI, magnetic resonance imaging; WHHL, Watanabe heritable hyperlipidemic.
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Figure 3 graph showing the SNR of the aortic wall specimens on in vitro MRI scans. 
Notes: Aortic specimens from WHHL rabbits (A) Controls; (B) dose 1, (C) dose 2, (D) dose 3 of D-USPIO; (E) dose 1, (F) dose 2, (G) dose 3 of DM-USPIO (dose 1: 
n = 1; dose 2: n = 1; dose 3: n = 3). Compared to the controls, the signal from the aortic wall decreased in rabbits injected with D- or DM-USPIO, in a dose-dependent 
manner. At dose 3, the SNR tended to be lower (*P , 0.1) in rabbits treated with DM-USPIO. The SNR value obtained from three ROIs on three different aortic images 
was significantly lower (**P , 0.05) in the rabbit treated with dose 2 DM-USPIO than in the rabbit treated with an equivalent dose of D-USPIO. There was no significant 
difference at dose 1 (P . 0.1). 
Abbreviations:  D-USPIO,  dextran-coated  ultrasmall  superparamagnetic  iron  oxide;  DM-USPIO,  mannan–dextran-coated  ultrasmall  superparamagnetic  iron  oxide; 
SNR, signal-to-noise ratio; ROI, region of interest.
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Figure 4 Prussian blue staining of histopathological sections. 
Notes: (A) dose 1, (B) dose 2, (C) dose 3 of D-USPIO; (D) dose 1, (E) dose 2, (F) dose 3 of DM-USPIO. There was a marked iron uptake in the arterial walls of all rabbits 
injected with either D- or DM-USPIO. The Prussian blue-stained area increased in both the D- and DM-USPIO group in a dose-dependent manner. 
Abbreviations: D-USPIO, dextran-coated ultrasmall superparamagnetic iron oxide; DM-USPIO, mannan–dextran-coated ultrasmall superparamagnetic iron oxide.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2276
Tsuchiya et alInternational Journal of Nanomedicine 2012:7
The iron concentration in inflammatory cells in plaques is 
sufficiently high for the production of dominant T2 and T2* 
effects, while its concentration in the blood pool is at levels at 
which T1 shortening effects predominate. In that study, iron 
particles were observed electron microscopically in actively 
phagocytosing cells, but not in inactive foam cells filled 
with fat vacuoles. These, and other observations, suggest 
that both D- and DM-USPIO are potential contrast agents 
for the diagnosis of atherosclerotic plaques – which exhibit 
high activity before the onset of luminal narrowing – and are 
potentially useful for the assessment of therapeutic effects 
of anti-atherosclerotic drugs, such as statins.
Macrophages and dendritic cells can be targeted by 
mannosylated nanoparticles because immune cells,   including 
alveolar and peritoneal macrophages, monocyte-derived 
dendritic cells, and Kupffer cells, constitutively express high 
levels of the mannose receptor (MR). Hashida and colleagues 
took the lead in the development of mannosylated liposomes to 
target macrophages and dendritic cells for delivery (in animal 
models) of the anti-inflammatory agent dexamethasone 
50 µM 
A  B 
50 µM 
Figure 5 (A) Prussian blue and (B) immunohistochemical (RAM11) staining of histopathological sections from WHHL rabbits injected with DM-USPIO at dose 3 (0.8 mmol Fe/Kg). 
Note: The localization of iron and macrophages was correlated. 
Abbreviations: DM-USPIO, mannan–dextran-coated ultrasmall superparamagnetic iron oxide; WHHL, Watanabe heritable hyperlipidemic.
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Figure 6 Iron-positive areas in the aortic wall of rabbits injected with D- or DM-USPIO.
Notes: At dose 3 (0.8 mmol Fe/Kg), the iron-positive areas were significantly larger in rabbits treated with DM- than in those treated with D-USPIO (*P , 0.05). The areas were 
significantly larger in different sections of the aorta from the rabbit injected with dose 1 or dose 2 DM- than in that treated with an equivalent dose of D-USPIO (*P , 0.05). 
Abbreviations: D-USPIO, dextran-coated ultrasmall superparamagnetic iron oxide; DM-USPIO, mannan–dextran-coated ultrasmall superparamagnetic iron oxide.
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palmitate and the CpG DNA complex.34,35 The study showed 
that intratracheally administered mannosylated liposomes, with 
various ratios of mannosylated cholesterol derivatives, were 
preferentially taken up by alveolar macrophages. Inhibition 
studies showed that mediation occurred via mannose receptor 
endocytosis. Mannosylation significantly improved liposome 
internalization by macrophages.36 Ross37 identified the presence 
and role of activated M1 macrophages in atherosclerosis. 
However, the presence of M2 macrophages in atherosclerotic 
lesions remained unknown. Bouhlel et al26 reported that 
markers of the M1 state (eg, MCP-1, IL-6, and TNF-α), and 
markers of M2 activation (eg, CD163, MR [also called CD206], 
AMAC1 [alternative macrophage activation-associated CC 
chemokine 1, also called chemokine ligand 18 (CCL-18)], 
and IL-10) are more abundantly expressed in the pathological 
tissues of atherosclerotic lesions than in the adjacent zone. We 
posit that our agent, DM-USPIO, exhibits a higher affinity for 
atherosclerotic lesions than does D-USPIO.
DM-USPIO D-USPIO
mgFe/L
3.5
3
2.5
2
1.5
1
0.5
0
Figure 7 Iron content per unit weight of aortic specimen from rabbits injected with D- or DM-USPIO at dose 3 (0.8 mmol Fe/Kg).
Note: There was no significant difference between the two groups. 
Abbreviations: D-USPIO, dextran-coated ultrasmall superparamagnetic iron oxide; DM-USPIO, mannan–dextran-coated ultrasmall superparamagnetic iron oxide.
60
50
40
30
20
10
0
D-USPIO
PG/Cell
DM-USPIO
*
Figure 8 Iron uptake in cultured J774.1 macrophage cells, measured by atomic absorption photometry. 
Note: The amount of intracellular iron was significantly higher in cells treated with DM-USPIO than with D-USPIO (*P , 0.05).
Abbreviations: D-USPIO, dextran-coated ultrasmall superparamagnetic iron oxide; DM-USPIO, mannan–dextran-coated ultrasmall superparamagnetic iron oxide.
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Our histological analyses showed that the uptake of 
DM- was higher than that of D-USPIO in the atherosclerotic 
wall of rabbits, resulting in a greater reduction of signal from 
the aortic wall in MRI scans. As the amount of intracellular 
iron was higher in macrophage cells treated with DM- rather 
than D-USPIO, we posit that macrophages contained in 
atherosclerotic plaques are more sensitive to DM- than to 
D-USPIO, making it possible to acquire plaque images at 
lower doses of contrast agent. We also found that the distribu-
tion of DM-USPIO in the liver and lung tended to be higher 
than that of D-USPIO, suggesting that receptor-mediated 
endocytosis had a strong role in the internalization of DM-
USPIO by macrophages. As mannose receptors are expressed 
in the liver and lung,34–36 it is not surprising that the distribu-
tion of DM-USPIO was higher than that of D-USPIO in these 
organs. We cannot rule out the possibility that increased dis-
tribution in these organs results in a reduction in the amount 
of circulating USPIO particles, and a consequent reduction 
in their presence in the aortic wall. However, based on our 
current findings, we suggest that the affinity of DM-USPIO 
particles for the aortic wall affects their uptake positively, and 
that the effect of reduced circulation of DM-USPIO due to its 
distribution in the liver and lungs is not strong. This is because 
the circulation lifetime of USPIOs is sufficiently prolonged, in 
accordance with particle size. On the other hand, the amount 
of iron per unit weight was not different irrespective of the 
type of USPIO used. We attributed this to technical difficul-
ties with our preliminary arrangements for making NMR 
measurements. For our NMR measurements, the uniformity 
of the samples was the most important issue because we used 
minute quantities of sample for measurement. Nevertheless, 
it was very difficult to obtain vessel homogenates because the 
vessels contained abundant fibers. Consequently,   insufficient 
preparation of uniform homogenate samples may have 
impacted our NMR measurements and caused inconsistency 
between NMR measurements and other examinations, such 
as imaging and histological analysis.
Our study has some limitations. First, the number of rabbits 
was too small to confirm the reproducibility of the observed 
aortic wall changes, and assessment of inter-individual 
differences was not possible. Second, the USPIO doses we 
used were too high for clinical applications; additional studies 
are necessary to identify appropriate human dose levels. Also, 
the imaging sequence was not optimized. (The use of a more 
T2*-weighted GRE sequence with longer echo times may 
enhance the sensitivity for iron-induced susceptibility effects. 
With such a sequence, even smaller iron accumulations can 
be detected. This may facilitate a further reduction in the 
contrast dose). Third, after the injection of D- and DM-USPIO 
particles, the signal from the aortic wall was very low and not 
uniform among the sites examined. ROI placement affects the 
results of imaging analysis, and ROI analysis of the aortic 
wall is subject to greater dispersions. In efforts to avoid this 
potential bias, we used the average result from three different 
ROIs in our SNR measurements. Fourth, the imaging effects 
we observed may be specific for WHHL rabbits.
The similarity between atherosclerotic plaque formation 
in rabbits and humans has been documented elsewhere.38–41 
We suggest that the observed differences in the uptake of 
DM- and D-USPIO by rabbit atherosclerotic lesions are 
attributable to the binding of mannan to USPIO. Further study 
is required to investigate the stability of bound mannan and 
to determine optimum dosage amounts.
Conclusion
The trapping of DM- and D-USPIO particles in the ath-
erosclerotic wall of rabbits was indicated by a remarkable 
decrease in SNR. Our histological and imaging analyses 
showed that DM-USPIO was taken up to a greater degree 
than D-USPIO. Based on our observations, we suggest that 
DM-USPIO is superior to D-USPIO for the study of athero-
sclerotic lesions.
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